Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (Stock code: 9989) has announced that the 2025 First Extraordinary General Meeting (EGM) will be convened on Tuesday, December 16, 2025, at 2:00 p.m. (Hong Kong time) at the Ballroom, L’Hermitage Hotel, 3031 Nanhai Boulevard, Nanshan District, Shenzhen, the PRC.

Key proposals to be reviewed include abolishing the Company’s supervisory committee and amending relevant articles of association and internal corporate governance measures. In addition, shareholders will vote on the election of Mr. Pu Hong as an independent non-executive director.

The H Share register of members will be closed from December 11 to December 16, 2025 (both days inclusive). Shareholders whose names appear on the register on December 16, 2025, may attend and vote. They may also appoint proxies by submitting the required documents to the H Share registrar no later than 24 hours before the meeting. The EGM is expected to last for less than half a day, and attendees are responsible for their own travel and accommodation arrangements.